Fortrea Reports $691.5 Million Q3 Revenue, $0.28 Adjusted EPS
Fortrea reported Q3 2026 revenue of $691.5M, up from a loss a year earlier, with adjusted EPS of $0.28. The company raised its full-year revenue and adjusted EBITDA guidance. Operating income was $15.0M, and adjusted EBITDA reached $58.0M. Fortrea's backlog was adjusted to $7.316B after a contract review.
How this was made
The 30-second read
Why it matters
The earnings release shows a turnaround to profitability and an upward revision of full‑year guidance, which may attract new investors and support the stock price.
Market read
First‑report earnings with upgraded guidance for a mid‑cap biotech, offering a potential short‑term trading opportunity.
What to watch
The $558M backlog reduction could signal underlying project delays that may affect future revenue quality.
Background
Fortrea Holdings Inc. (FTRE) is a clinical‑trial services provider that filed its Q3 2026 earnings via an 8‑K.
Ticker impact
Fortrea reported Q3 2026 revenue of $691.5M, GAAP net income of $0.6M and raised its full-year revenue and EBITDA guidance.
likely upward pressure as the market prices in the raised guidance and profit turnaround.
The company posted a profit after a loss year‑over‑year and increased its full‑year outlook, which typically drives buying interest.
Market effects
Improves outlook for the clinical‑trial services sector as Fortrea signals stronger bookings momentum.
May boost sentiment for U.S. biotech stocks in the near term.
Limited to investors tracking mid‑cap biotech earnings.
Counterpoint
If the guidance raise is already priced in, the stock could face a pull‑back on the next trading day.
Key entities
- CompanyFortrea Holdings Inc.
Clinical‑trial services provider reporting Q3 results.
